Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04631601
Title Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Amgen

prostate adenocarcinoma


AMG 160 + AMG 404

AMG 160 + Enzalutamide

Abiraterone + AMG 160

AMG 404

Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.